Photo from archive.org
Highlights • Optimal dosing interval of bone-targeting agents (BTAs) has not been fully defined.• Study of 4 vs 12-weekly BTAs in breast or prostate cancer pts with bone metastases.• Study… Click to show full abstract
Highlights • Optimal dosing interval of bone-targeting agents (BTAs) has not been fully defined.• Study of 4 vs 12-weekly BTAs in breast or prostate cancer pts with bone metastases.• Study arms showed no significant differences SSE rates, time to SSEs or toxicity.• There were however significant differences in cost-effectiveness results.• On study SSE (12-weekly arm) associated with slight increase in subsequent SSEs.
Keywords:
bone metastases;
two year;
prostate cancer;
bone;
year results
Journal Title: Journal of Bone Oncology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Bone Oncology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!